摘要:SNMMI操作标准/EANM实践指南:使用16α-[18F]氟-17β-雌二醇PET对乳腺癌患者进行雌激素受体显像
雌激素受体(ER)在约70%的乳腺癌中表达,是重要的治疗靶点。16α-[18F]氟-17β-雌二醇([18F]FES)已在法国和美国获批临床使用,[18F]FES PET可评估肿瘤ER表达、预测ER靶向治疗反应并帮助明确分期。SNMMI与EANM于2023年6月发布了乳腺癌[18F]FES PET ER显像的操作标准/实践指南,旨在帮助医生推荐、执行、解读和报告检查结果,并促进多中心试验中的标准化应用。
要点
- 约70%的乳腺癌初诊时表达ER,组织检测(通常为免疫组化)是标准诊疗的一部分。
- [18F]FES已在法国和美国获批临床使用,[18F]FES PET可评估肿瘤ER表达并预测ER靶向治疗反应。
- [18F]FES PET/CT可能有助于浸润性小叶癌和低级别ER表达浸润性导管癌的分期,某些情况下可替代活检。
核心结论
- 该操作标准/实践指南旨在帮助医生推荐、执行、解读和报告乳腺癌患者的[18F]FES PET检查结果,并提供最佳可用证据、告知证据缺乏的领域。
- 标准化影像流程结合已发表的适当使用标准,将有助于推广[18F]FES PET并促进后续研究。
研究设计与样本
- 由美国核医学与分子影像学会(SNMMI)和欧洲核医学协会(EANM)于2023年6月联合发布的操作标准/实践指南。
- 指南涵盖[18F]FES PET的标准化质量控制、质量保证和影像流程。
主要发现
- 多项研究提示[18F]FES PET在评估肿瘤ER表达方面的优势。
- 定性及定量[18F]FES PET指标均能预测ER靶向治疗反应。
- [18F]FES PET能帮助明确ER表达癌症患者中模棱两可的分期和再分期结果。
关键数值与推荐
- 约70%的乳腺癌初诊时表达ER,组织检测(通常为免疫组化)是新诊断乳腺癌标准诊疗的一部分。
- 18F]FES已获法国和美国监管机构批准临床使用。
- 指南强调精确性、准确性、可重复性和重现性对患者临床管理及多中心试验中[18F]FES PET应用的重要性。
临床怎么用
- 该标准/指南旨在协助医生推荐、执行、解读和报告乳腺癌患者的[18F]FES PET检查结果。
- [18F]FES PET/CT可能有助于浸润性小叶癌和低级别ER表达浸润性导管癌的分期,某些情况下可替代活检。
- 标准化影像流程结合已发表的适当使用标准,有助于推广[18F]FES PET并促进后续研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The estrogen receptor (ER), a steroid hormone receptor important in female physiology, is a significant contributor to breast carcinogenesis and progression and, as such, is an important therapeutic target. Approximately 70% of breast cancers will express ER at presentation, and the determination of ER expression by tissue assay, usually by immunohistochemistry, is part of the standard of care for newly diagnosed breast cancer. ER expression is important in guiding the approach to treatment, especially with the increase in relevant systemic therapies. The ER-targeting imaging agent 16α-[18F]fluoro-17β-estradiol ([18F]FES) is approved for clinical use by regulatory agencies in France and the United States. Multiple studies suggest the advantages of [18F]FES PET in assessing tumor ER expression, the ability of both qualitative and quantitative [18F]FES PET measures to predict response to ER-targeted therapy, and the ability of [18F]FES PET to clarify equivocal staging and restaging results in patients with ER-expressing cancers. [18F]FES PET/CT may also be helpful in staging invasive lobular breast cancer and low-grade ER-expressing invasive ductal cancers and, in some cases, may be a substitute for biopsy. The Society of Nuclear Medicine and Molecular Imaging and the European Association of Nuclear Medicine in June 2023 released a procedure standard/practice guideline for [18F]FES PET ER imaging of patients with breast cancer. The goal of the standard/guideline is to assist physicians in recommending, performing, interpreting, and reporting the results of [18F]FES PET studies for patients with breast cancer and to provide clinicians with the best available evidence, inform them about areas where robust evidence is lacking, and help them deliver the best possible diagnostic efficacy and study quality for their patients. Also reviewed are standardized quality control, quality assurance, and imaging procedures for [18F]FES PET. The authors emphasize the importance of precision, accuracy, repeatability, and reproducibility for both clinical management of patients and for use of [18F]FES PET in multicenter trials. A standardized imaging procedure, in combination with already published appropriate-use criteria, will help promote the use of [18F]FES PET and enhance subsequent research. This brief summary article reviews the content of the joint standard/guideline, which is available in its entirety at https://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=6414&navItemNumbe=10790.
引用
- Mankoff D, Balogová S, Dunnwald L, et al. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[18F]Fluoro-17β-Estradiol PET. J Nucl Med. 2024. PMID: 38071554. doi:10.2967/jnumed.123.266938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。